Overview

A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria

Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing albuminuria in patients with Chronic Kidney Disease with Type 2 Diabetes.
Phase:
Phase 2
Details
Lead Sponsor:
Ardelyx
Collaborator:
AstraZeneca